T cell activity in chronic urticaria treatment with omalizumab
Author Information
Author(s): Sánchez-Machín Inmaculada, Iglesias-Souto Javier, Franco Andrés, Barrios Yvelise, Gonzalez Ruperto, Matheu Víctor
Primary Institution: Alergología, Hospital del Tórax (Ofra); Complejo Hospitalario Universitario NS Candelaria, S/C Tenerife, Spain
Hypothesis
Can omalizumab alter T cell activity in patients with chronic urticaria?
Conclusion
Omalizumab may be effective in treating severe chronic urticaria and can increase CD4+ T cell activity.
Supporting Evidence
- Omalizumab treatment led to a significant decrease in urticarial lesions within 2 days.
- CD4+ T cell activity increased significantly after omalizumab treatment.
- The patient remained asymptomatic without medication after treatment.
Takeaway
A woman with severe hives got better after taking a medicine called omalizumab, which helped her immune cells work better.
Methodology
The patient's T cell activity was measured by assessing ATP release from CD4+ T cells before and after omalizumab treatment.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
One 35-year-old woman with chronic idiopathic urticaria.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website